These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 21411546

  • 1. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
    Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA.
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1763-70. PubMed ID: 21411546
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S, Astiarraga B, Tura A, Frascerra S, Ciociaro D, Mari A, Gastaldelli A, Ferrannini E.
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [Abstract] [Full Text] [Related]

  • 6. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD.
    Am J Health Syst Pharm; 2005 Jan 15; 62(2):173-81. PubMed ID: 15700891
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
    Curr Med Res Opin; 2008 Oct 15; 24(10):2943-52. PubMed ID: 18786299
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.
    Khoo EY, Wallis J, Tsintzas K, Macdonald IA, Mansell P.
    Diabetologia; 2010 Jan 15; 53(1):139-43. PubMed ID: 19898831
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Six and 12 Weeks of Caloric Restriction Increases β Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes.
    Sathananthan M, Shah M, Edens KL, Grothe KB, Piccinini F, Farrugia LP, Micheletto F, Man CD, Cobelli C, Rizza RA, Camilleri M, Vella A.
    J Nutr; 2015 Sep 15; 145(9):2046-51. PubMed ID: 26246321
    [Abstract] [Full Text] [Related]

  • 18. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K, Okada Y, Mori H, Otsuka T, Kawaguchi M, Matsuda M, Kuno F, Sugai K, Sonoda S, Hajime M, Tanaka K, Arao T, Tanaka Y.
    Cardiovasc Diabetol; 2015 Feb 18; 14():25. PubMed ID: 25849903
    [Abstract] [Full Text] [Related]

  • 19. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
    Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R.
    Diabetes Obes Metab; 2014 Feb 18; 16(2):170-8. PubMed ID: 23911196
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial.
    Ang M, Linn T.
    Am J Clin Nutr; 2014 Oct 18; 100(4):1059-68. PubMed ID: 25030779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.